# EDGAR Filing Document

**Accession Number:** 0001395064
**File Stem:** 0001395064-25-000122
**Filing Date:** 2025-7
**Character Count:** 9701
**Document Hash:** a06aa93cb94b221bc0fb839889ada2b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001395064-25-000122.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001395064-25-000122

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 6

**CONFORMED PERIOD OF REPORT**: 20250731

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TAKEDA PHARMACEUTICAL CO LTD
- **CENTRAL INDEX KEY:** 0001395064
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38757
- **FILM NUMBER:** 251169125

**BUSINESS ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668
- **BUSINESS PHONE:** 81332782111

**MAIL ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668

**FORM 6-K**

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of**

**the Securities Exchange Act of 1934**

**For the month of July 2025**

**Commission File Number: 001-38757**

**TAKEDA PHARMACEUTICAL COMPANY LIMITED**

**(Translation of registrant's name into English)**

**1-1, Nihonbashi-Honcho 2-Chome**

**Chuo-ku, Tokyo 103-8668**

**Japan**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

Information furnished on this form:

**EXHIBIT**

---

| | |
|:---|:---|
| Exhibit<br>Number | |
| 99.1 | <u>[Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress](statement.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **TAKEDA PHARMACEUTICAL COMPANY LIMITED** | **TAKEDA PHARMACEUTICAL COMPANY LIMITED** |
| Date: July 31, 2025 | By: | /s/ Norimasa Takeda |
|  |  | Norimasa Takeda<br>Chief Accounting Officer and Corporate Controller |

---

## Exhibit 99.1

![](statement001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statement Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress Osaka, JAPAN and CAMBRIDGE, Massachusetts, July 31, 2025 – An embargoed version of an abstract for our Phase 3 TAK-861-3002 study (RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1, which is slated to be presented at the upcoming World Sleep 2025 congress in September, was inadvertently published by the World Sleep Congress on their website. Once we became aware, we reached out to World Sleep and they have since removed the abstract. This abstract is only one of several abstracts from our Phase 3 studies that will be presented at the conference. We look forward to sharing the positive results from both of our Phase 3 studies at World Sleep, which, as previously disclosed, met all of the primary and secondary endpoints across all doses at week 12. These results reinforce the potential of oveporexton to transform the standard of care for people with narcolepsy type 1. In the spirit of transparency, we are also providing the abstract that was inadvertently published as an attachment. Takeda does not anticipate any significant impact on its consolidated financial results as a result of this matter. ###

------

![](statement002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title Efficacy and Safety of Oveporexton (TAK-861) for the Treatment of Narcolepsy Type 1: Results from a Phase 3 Randomized Study in Asia, Australia and Europe. Authors Yves Dauvilliers1,2,3, Jakub Antczak4, Erik Buntinx5, Rafael del Rio Villegas6,7, Seung-Chul Hong8, Sheila Sivam9, Shuqin Zhan10, Elena Koundourakis11, Rachel Neuwirth11, Tina Olsson11, Sarah Sheikh11, Philipp von Rosenstiel11, Baiyun Yao11, Alice Cai11\*, Giuseppe Plazzi12,13\* Affiliations 1Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, CHU, Montpellier, France; ydauvilliers@yahoo.fr 2Institute of Neurosciences of Montpellier, INSERM, University of Montpellier, France 3National Reference Network for Narcolepsy, Montpellier, France 4Jagiellonian University, Kraków, Poland; jakub.antczak@uj.edu.pl 5ANIMA Research, Alken, Belgium; erik.buntinx@anima-alken.be 6Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid, Spain; rafaeldelrio@movistar.es 7Universidad CEU San Pablo, CEU Universities, Madrid, Spain 8Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea; hscjohn@hotmail.com 9Woolcock Institute of Medical Research and Royal Prince Alfred Hospital, Sydney, NSW, Australia; sheila.sivam@sydney.edu.au 10Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China; shqzhan@hotmail.com 11Takeda Development Center Americas, Inc., Cambridge, MA, USA; Elena.Koundourakis@Takeda.com; Rachel.Neuwirth@Takeda.com; tina.olsson@takeda.com; sarah.sheikh@takeda.com; baiyun.yao@takeda.com; alice.cai@takeda.com 12Department of Biomedical, Metabolic and Neural Sciences, University of Modena and (Attachment)

------

![](statement003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;2 Reggio-Emilia, Modena, Italy; giuseppe.plazzi@unibo.it 13IRCCS, Istituto delle Scienze Neurologiche, Bologna, Italy \*Shared last author Presenter: Yves Dauvilliers Abstract word count: 500/500 (includes acknowledgments) Introduction Narcolepsy type 1 (NT1) is a chronic, rare, neurologic disorder of hypersomnolence caused by loss of orexin-producing neurons in the hypothalamus, which regulate wakefulness, sleep, and attention through activation of orexin receptors. NT1 results in a range of symptoms including excessive daytime sleepiness, sudden muscle weakness (cataplexy), disrupted nighttime sleep, sleep paralysis, hypnagogic/hypnopompic hallucinations, and cognitive symptoms. Orexin receptor agonists are promising treatments for NT1 as currently available therapies do not target orexin deficiency. Oveporexton (TAK-861) is an investigational oral orexin receptor 2 (OX2R)-selective agonist that stimulates OX2R to restore signaling and address the underlying orexin deficiency. In a previous phase 2b study, oveporexton delivered improvements across the spectrum of NT1 symptoms, assessed by both objective and patient-reported measures, and was generally well tolerated. Here, we report first results from a phase 3 study that evaluated the efficacy, safety and impact on functioning, quality of life and cognition of oveporexton in participants with NT1. Materials and methods In this double-blind, placebo-controlled, phase 3 study (TAK-861-3002) participants were randomized 2:1 to oral oveporexton 2 mg or placebo twice daily at least 3 hours apart for 12 weeks. At the end of treatment, participants either entered the long-term extension or completed 4 weeks of follow up. Key inclusion criteria included: age 16–70 years; International Classification of Sleep Disorders, Third Edition (ICSD-3) or ICSD-3-text revision diagnosis of NT1 supported by polysomnography, multiple sleep latency testing (MSLT) or orexin cerebrospinal fluid (CSF) concentrations ≤110 pg/mL; Epworth Sleepiness Scale (ESS) score ≥11; and ≥4 partial/complete episodes of cataplexy/week. The primary endpoint was change from baseline in mean sleep latency on the Maintenance of Wakefulness Test (MWT) at week 12. Secondary endpoints included change from baseline in ESS total score at week 12, weekly cataplexy rate (WCR) at week 12, and occurrence of treatment-emergent adverse events (TEAE).

------

![](statement004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;3 Results Overall, 105 participants (50 [47.6%] female) were enrolled across Asia, Australia, and Europe; 70 were randomized to oveporexton 2 mg/2 mg and 35 to placebo. At baseline, mean age was 30.7 years, mean ESS score was 17.5, mean MWT sleep latency was 4.5 minutes and median WCR was 23.5 attacks/week. At week 12, significant least square (LS) mean (95% CI) changes from baseline were achieved with oveporexton 2mg/2mg vs placebo in MWT sleep latency (20.09 [16.57, 23.61] minutes, P<0.001 vs placebo). Significant changes vs placebo were also achieved at week 12 for ESS total score (LS mean [95% CI] change from baseline: -9.53 [-11.10, -7.97], P<0.001) and WCR (Incidence rate ratio [95% CI] vs placebo: 0.25 [0.15, 0.42], P<0.001). Sixty (85.7%) oveporexton-treated participants experienced ≥1 TEAEs vs 15 (42.9%) placebo-treated participants; there were no serious TEAEs. The most common TEAEs with oveporexton were pollakiura (43 [61.4%]) and insomnia (40 [57.1%]). 101 (96.2%) completed study treatment, of which 100 (99.0%) enrolled into the long-term extension. Conclusions In this phase 3 study, oveporexton treatment resulted in significant improvements on measures of sleepiness and cataplexy frequency with oveporexton versus placebo, and was generally well tolerated. Acknowledgments Funded by Takeda Development Center Americas, Inc.

------